Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Sanofi MS drug nears green light after pass-the-parcel marathon
Amiloride: a molecular probe of sodium transport in tissues and cells.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
Alerting Network Dysfunction in Early Multiple Sclerosis.
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Clinical profile of malay children with optic neuritis.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Neuroprotective effect of masitinib in rats with postischemic stroke.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Idebenone for primary progressive multiple sclerosis
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.

Pages